{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:20:56Z","timestamp":1760188856225},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":7192,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1986,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>One hundred fifty\u2010eight hemophilia A, B, and von Willebrand disease (VWD) patients treated with clotting factor concentrates from a single manufacturer were tested for antibody to the human T\u2010lymphotropic virus type III (HTLV\u2010III). Antibody was detected in 63% and 40% of those with severe hemophilia A and B, respectively 12% and 0% of those with mild hemophilia A and B, and two patients with recessive VWD. Forty\u2010two antibody\u2010positive and 20 antibody\u2010negative patients were studied for clinical and laboratory features of infection. Eleven seropositive patients had clinical signs of infection including <jats:italic>Pneumocystis carinii<\/jats:italic> pneumonia, lymphadenopathy, splenomegaly or diarrhea; however, only one patient had developed acquired immune deficiency syndrome (AIDS), and only two had significant impairment of their performance status. Thirty\u2010one patients remained totally asymptomatic. Eight patients had a history suggestive of acute HTLV\u2010III infection. Thrombocytopenia was observed in 18% of seropositive patients, lymphopenia in 60%, depressed T\u2010helper cells in 43%, reduced T\u2010helper: T\u2010suppressor ratios (TH: TS) in 33%, and elevated platelet\u2010bound immunoglobulin in 53%. The antibody\u2010negative group had normal T\u2010helper cell levels (except one patient) and TH: TS ratios, and normal platelet immunoglobulin levels. Both groups demonstrated a significant elevation of immunoglobulin levels and a high prevalence of antinuclear factor and antismooth muscle antibodies. The mean level of IgG was significantly higher in the antibody\u2010positive group. This study confirms the correlation between HTLV\u2010III infection and reduced T\u2010helper cells in hemophiliacs but demonstrates a low incidence of clinical symptomatology. There was evidence of polyclonal B\u2010cell hyperactivity in the antibody\u2010negative group as well as the seropositive group.<\/jats:p>","DOI":"10.1002\/ajh.2830230308","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T10:43:26Z","timestamp":1172054606000},"page":"239-245","source":"Crossref","is-referenced-by-count":12,"title":["Spectrum of HTLV\u2010III infection in a hemophilic cohort treated with blood products from a single manufacturer"],"prefix":"10.1002","volume":"23","author":[{"given":"Katherine M.","family":"McGrath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.253.23.3409"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1985.tb122758.x"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6497.695"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90288-0"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112312"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91205-X"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1978.tb01089.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(81)90281-5"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.5.1653"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198301133080205"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1984.tb37181.x"},{"key":"e_1_2_1_13_2","first-page":"653","article-title":"Some complications of the therapy of classic hemophilia","volume":"103","author":"Ratnoff OD","year":"1984","journal-title":"J Lab Clin Med"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198302243080808"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830230308","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830230308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T01:44:27Z","timestamp":1697852667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830230308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,11]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1986,11]]}},"alternative-id":["10.1002\/ajh.2830230308"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830230308","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,11]]}}}